News

At least 21 former staffers of the U.S. Digital Service resigned Tuesday, citing the agency’s takeover by Elon Musk’s ...
99% 12-month and 96% 36-month disease-specific survival in papillary NMIBC without CIS. 10-year cystectomy-free status observed in long-term follow-up of Phase 1 trial. Get our list of 10 ...
Shares of ImmunityBio touched a 52-week low after the company received a refusal-to-file letter from the Food and Drug Administration for a supplemental biologics license application for bladder ...
--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug ...